| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 164.55% | Mizuho | $17 → $10 | Maintains | Buy |
| 08/10/2023 | 111.64% | HC Wainwright & Co. | $11 → $8 | Maintains | Neutral |
| 08/09/2023 | 191.01% | JP Morgan | $10 → $11 | Maintains | Neutral |
| 08/08/2023 | 508.47% | Roth MKM | → $23 | Reiterates | → Buy |
| 07/26/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
| 06/30/2023 | 508.47% | Roth MKM | → $23 | Reiterates | Buy → Buy |
| 06/30/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
| 06/30/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
| 06/27/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
| 06/22/2023 | 323.28% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/07/2023 | 376.19% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 05/31/2023 | 508.47% | Roth MKM | → $23 | Initiates Coverage On | → Buy |
| 05/19/2023 | 191.01% | HC Wainwright & Co. | → $11 | Reiterates | Neutral → Neutral |
| 05/16/2023 | 164.55% | JP Morgan | $9 → $10 | Maintains | Neutral |
| 05/16/2023 | 349.74% | JMP Securities | $17 → $17 | Reiterates | Market Outperform → Market Outperform |
| 05/08/2023 | 376.19% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 03/29/2023 | 349.74% | JMP Securities | → $17 | Reiterates | → Market Outperform |
| 03/29/2023 | 138.1% | JP Morgan | $6 → $9 | Maintains | Neutral |
| 03/29/2023 | 191.01% | HC Wainwright & Co. | $7 → $11 | Maintains | Neutral |
| 02/14/2023 | 349.74% | JMP Securities | → $17 | Initiates Coverage On | → Market Outperform |
| 02/07/2023 | 402.65% | UBS | → $19 | Initiates Coverage On | → Buy |
| 12/29/2022 | 85.19% | HC Wainwright & Co. | $6 → $7 | Maintains | Neutral |
| 12/20/2022 | 270.37% | Goldman Sachs | $9 → $14 | Maintains | Buy |
| 09/28/2022 | 138.1% | Goldman Sachs | $4 → $9 | Maintains | Buy |
| 09/12/2022 | 58.73% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Neutral |
| 03/23/2022 | 58.73% | JP Morgan | $19 → $6 | Downgrades | Overweight → Neutral |
| 08/18/2021 | 402.65% | JP Morgan | $32 → $19 | Maintains | Overweight |
| 03/02/2021 | 746.56% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
| 03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 03/02/2021 | 667.2% | Goldman Sachs | → $29 | Initiates Coverage On | → Buy |
What is the target price for Terns Pharma (TERN)?
The latest price target for Terns Pharma (NASDAQ: TERN) was reported by Mizuho on November 27, 2023. The analyst firm set a price target for $10.00 expecting TERN to rise to within 12 months (a possible 164.55% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Terns Pharma (TERN)?
The latest analyst rating for Terns Pharma (NASDAQ: TERN) was provided by Mizuho, and Terns Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Terns Pharma (TERN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating Terns Pharma (TERN) correct?
While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a maintained with a price target of $17.00 to $10.00. The current price Terns Pharma (TERN) is trading at is $3.78, which is out of the analyst's predicted range.